Market Overview

Leerink Swann Reiterates Outperform On Rigel Pharma As Shares Plunge 12+% On Missed R343 Trial Endpoints

Related RIGL
Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ritchie Bros. Shares Spike Higher
18 Biggest Mid-Day Gainers For Tuesday
18% of patients in Rigel Pharma's late-stage study of fostamatinib in immune thrombocytopenia achieve stable platelet count; rate of treatment-related adverse events 77%; shares up 5% premarket (Seeking Alpha)

Shares of Rigel Pharma (NASDAQ: RIGL) have traded down around 12-13 percent throughout Monday morning's trading session following some concerning data from a trial of its R343. Rigel shares have bounced sharply from the pre-market low under $2.50.

Analyst Marko Kozul at Leerink Swann, a firm which specializes in the Pharma group, said he was surprised by the failure of the R343 trial to miss the primary and secondary endpoints.

Although the analyst was caught off guard, he cited low expectations for the remaining three catalysts over the near term for his reiterated Outperform rating. Kozul adjusted his price target on Rigel Pharma lower from $7 previously to $5.

With Rigel shares down to around $3.18 at last check, Kozul's new, lowered price target still represents potential upside of nearly 60 percent.

Latest Ratings for RIGL

Aug 2016BMO CapitalInitiates Coverage onOutperform
Jul 2016H.C. WainwrightInitiates Coverage onBuy
Jun 2016Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Reiteration FDA Analyst Ratings Movers


Related Articles (RIGL)

View Comments and Join the Discussion!